Vivelle-Dot® (Estradiol)

Transdermal Patch (Commercial Product)

Available Dosage Strengths

0.025 mg/day | 0.0375 mg/day | 0.05 mg/day | 0.075 mg/day | 0.1 mg/day

Want to Prescribe?

Disclaimer: Images are for reference only; actual products may vary.

Product Overview

Description

Vivelle-Dot® (Estradiol) Description^1-6

Micronized estradiol is a bioidentical form of 17β-estradiol, the primary estrogen produced by the ovaries in premenopausal women. It is used in a variety of hormone therapy (HT) regimens and can be considered one of the preferred estrogen formulations for menopausal women due to its bioidentical structure and favorable risk profile when appropriately prescribed. When applied topically and absorbed transdermally, micronized estradiol does not undergo first-pass metabolism through the liver, this leads to the favorable risk profile as the first pass-effect of estradiol causes the greatest increases in thromboembolic factors. Vivelle-Dot® (estradiol transdermal system) contains estradiol in a multipolymeric adhesive. The system is designed to release estradiol continuously upon application to intact skin.

Vivelle-Dot® (estradiol transdermal system) has the following indications 1) Treatment of moderate-to-severe vasomotor symptoms associated with the menopause; 2) Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause; 3) Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure; and 4) Prevention of postmenopausal osteoporosis.

References

Cynthia A. Stuenkel, Susan R. Davis, Anne Gompel, Mary Ann Lumsden, M. Hassan Murad, JoAnn V. Pinkerton, Richard J. Santen, Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, Volume 100, Issue 11, 1 November 2015, Pages 3975–4011, accessed July 2025 through: https://doi.org/10.1210/jc.2015-2236
Estradiol transdermal system (Vivelle-Dot) https://www.novartis.com/us-en/sites/novartis_us/files/Vivelle_DOT.pdf Distributed by: Novartis Pharmaceuticals Corporation East Hanover, NJ 07936 Approved October 2021. Accessed July 5, 2026.
North American Menopause Society (NAMS) Position Statement (2022): “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” https://www.menopause.org/docs/default-source/professional/2022-nams-ht-position-statement.pdf
Sobel TH, Shen W. Transdermal estrogen therapy in menopausal women at increased risk for thrombotic events: a scoping review. Menopause. 2022 Jan 14;29(4):483-490. doi: 10.1097/GME.0000000000001938. PMID: 35357370.
Canonico, M., Oger, E., Plu-Bureau, G., Conard, J., Meyer, G., Lévesque, H., … & Scarabin, P. Y. (2007). Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation, 115(7), 840-845.
Clinical Pharmacology estradiol clinical monograph accessed July 2025 through: https://www.clinicalkey.com/pharmacology/monograph/1330?n=Estradiol Accessed July 5, 2026

Mechanism of Action

Mechanism of Action^1-6

Estradiol binds to estrogen receptors, which are widely distributed in reproductive tissues, the brain, bone, liver, and vasculature. Upon receptor binding, estradiol influences gene transcription, leading to a broad range of systemic and local effects:

Endometrial stimulation: Promotes proliferation in the endometrial lining.
Thermoregulatory effects: May relieve hot flashes by stabilizing hypothalamic activity.
Bone preservation: May reduce osteoclast-mediated bone resorption, maintaining bone mineral density.
Vaginal and urogenital health: Helps to maintain epithelial integrity, pH balance, and blood flow.
Neuroprotection: Modulates neurotransmitter systems that affect mood, cognition, and sleep.
Cardiovascular modulation: Promotes vasodilation and improves lipid profile, although the route of administration affects cardiovascular risk.

Adverse Reactions

Common^1-6

Breast tenderness
Nausea
Headache
Bloating or fluid retention
Breakthrough vaginal bleeding
Mood swings
Less Common / Serious Risks:
Increased risk of venous thromboembolism (VTE) (primarily with oral use)
Gallbladder disease
Endometrial hyperplasia or cancer if unopposed by a progestogen in women with a uterus

Contraindications & Precautions

Contraindications^1-7

Undiagnosed abnormal genital bleeding
Active or history of estrogen-dependent cancer (e.g., breast, endometrial)
Active or recent thromboembolic disorders (e.g., DVT, PE, stroke, heart attack)
Active liver disease
Known hypersensitivity to estradiol or formulation components

Precautions^1-7

Use caution in women with:

Controlled hypertension
Migraine with aura
Hypertriglyceridemia
Diabetes mellitus
History of gallbladder disease
History of or active hormone-sensitive cancers (in remission)

*Use with Progesterone: For women with an intact uterus, progesterone in some form should be included with systemic estradiol therapy to prevent endometrial hyperplasia or carcinoma.

Storage

Store at controlled room temperature (20°C to 25°C / 68°F to 77°F)
Protect from moisture and light
Keep in a tightly closed container

References

Cynthia A. Stuenkel, Susan R. Davis, Anne Gompel, Mary Ann Lumsden, M. Hassan Murad, JoAnn V. Pinkerton, Richard J. Santen, Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, Volume 100, Issue 11, 1 November 2015, Pages 3975–4011, accessed July 2025 through: https://doi.org/10.1210/jc.2015-2236
Estradiol transdermal system (Vivelle-Dot) https://www.novartis.com/us-en/sites/novartis_us/files/Vivelle_DOT.pdf Distributed by: Novartis Pharmaceuticals Corporation East Hanover, NJ 07936 Approved October 2021. Accessed July 5, 2026.
North American Menopause Society (NAMS) Position Statement (2022): “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” https://www.menopause.org/docs/default-source/professional/2022-nams-ht-position-statement.pdf
Sobel TH, Shen W. Transdermal estrogen therapy in menopausal women at increased risk for thrombotic events: a scoping review. Menopause. 2022 Jan 14;29(4):483-490. doi: 10.1097/GME.0000000000001938. PMID: 35357370.
Canonico, M., Oger, E., Plu-Bureau, G., Conard, J., Meyer, G., Lévesque, H., … & Scarabin, P. Y. (2007). Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation, 115(7), 840-845.
Clinical Pharmacology estradiol clinical monograph accessed July 2025 through: https://www.clinicalkey.com/pharmacology/monograph/1330?n=Estradiol Accessed July 5, 2026

Disclaimer

This information is for educational purposes only.

Wells Pharmacy Network distributes certain FDA-approved commercial products that are manufactured by third-party pharmaceutical companies. These products are not compounded or manufactured by Wells Pharmacy Network. Product availability at the time of dispensing may vary due to supply chain conditions.

This information is a summary. It may not cover all possible drug information about this product. For complete product information, refer to the manufacturer’s prescribing information and labeling. Call your doctor for medical advice and/or about side effects. You may report side effects to the FDA at 1-800-FDA-1088. A Wells Pharmacy Network pharmacist will be happy to answer any questions. For consultation, please call 1-800-622-4510.